Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

FACCT Trial
  NCT04392973		 RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
125/129 inconclusive
  • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Shinkai
  JapicCTI-205238		 RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
107/49 safety concern
  • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
AVIFAVIR
  NCT04434248		 RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
20/20 suggested
  • suggested 2.9-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
Adverse drug reactions to AVIFAVIR were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) patients.
Dabbous HM
  NCT04349241		 RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
50/50 inconclusive
    NCT04542694
          NCT04542694    		 RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
    		100/100 suggested
    • suggested 1.1-fold increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 12.0-fold increase in viral clearance with a moderate degree of certainty due to some concern in risk of bias
    Ruzhentsova T
          NCT04501783    		 RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
    		112/56 suggested
    • suggested 63 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 28 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 28 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 50 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
    Udwadia
          CTRI/2020/05/025114    		 RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
    		75/75 safety concern
    • inconclusive 37 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 75 % increase in clinical improvement,clinical improvement (time to event analysis only),clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 94 % decrease in mechanical ventilation (time to event analysis only),mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 5.4-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    2 studies excluded by filtering options (2 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons